Fig. 2.

Cumulative HCC incidence rates in patients with SVR according to antiviral therapy. The Kaplan-Meier method was used to assess cumulative incidence rate of HCC, and the log-rank test was used to compare them (A). Nonparametric bootstrap test with pooled resampling method was performed to reduce the sample bias, as well as to verify the results of survival analysis. Briefly, the SVR patients were randomly drawn from the study population, and sampling was performed with replacement. From this sample the regression coefficients from COX proportional hazard model analyses were calculated. The resulting sample of effects then was used to calculate the 95% CI. If zero wasn’t included in the 95% CI, it represented the two treatments were different by means of HCC incidence. After 1000 bootstrap samples, HR of DAAs therapy for HCC occurrence was significantly higher than PR therapy for their lower ends of 95% CI were above zero (B).